PMAIP1 and Miyoshi myopathy: Based on our in vitro findings, we analyzed CD138-sorted MM cells from patients with acquired resistance in order to understand the impact of sXBP1, GRP78, and p53/NOXA in therapy responses after proteasome inhibition.